Korean journal of aerospace and environmental medicine (항공우주의학회지)

Aerospace Medical Association of Korea (한국항공우주의학협회)
권호 표지
DOI QR코드

DOI QR Code

Renal Cell Carcinoma: Case Report and Aeromedical Consideration

신장암: 증례보고 및 항공의학적 고찰

  • Song, Joon Ho (Department of Interna Medicine, Inha University School of Medicine)
  • 송준호 (인하대학교 의과대학 내과학교실)
  • Received : 2021.12.16
  • Accepted : 2021.12.24
  • Published : 2021.12.31
⟨ Previous Next ⟩

Abstract

Renal cell carcinoma (RCC) is common primary tumor of kidney. In the past, it had been considered a difficult tumor to manage since the detection was usually delayed until paraneoplastic syndrome and/or distant metastasis appeared due to its slow progression. However, the recent popularization of ultrasound and computed tomography has made RCC one of the easily curable cancers. Eighty percent are found early, mostly with tumor size less than 5 cm. Five-year survival rate after successful nephrectomy is exceeded 80-90 percent. Curative nephrectomy can be tried in stage 1 and 2, and some cases of stage 3. In these cases, return to flight can be considered after 6 to 12 months' observation. It should be monitored any occurrence of cancer recurrence, need for systemic treatment, metastasis, and paraneoplastic syndrome, etc. If any signs of recurrence are found or new treatment needs to be initiated, the flight should be suspended. If there is no recurrence for more than 5 to 10 years, the patient doesn't have to be followed anymore.

Keywords

References

  1. Federal Aviation Administration. Guide for aviation medical examiners [Internet]. Washington, D.C.: Federal Aviation Administration; 2021 [updated 2021 Nov 24; cited 2021 Dec 1]. Available from: www.faa.gov/about/office_org/headquarters_offices/avs/offices/aam/ame/guide/.
  2. Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin 2017;67:507-524. https://doi.org/10.3322/caac.21411
  3. Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol 2009;182:854-859. https://doi.org/10.1016/j.juro.2009.05.017
  4. Siddiqui SA, Frank I, Leibovich BC, Cheville JC, Lohse CM, Zincke H, et al. Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol 2007;177:59-62. https://doi.org/10.1016/j.juro.2006.08.069
  5. Chevinsky M, Imnadze M, Sankin A, Winer A, Mano R, Jakubowski C, et al. Pathological stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma. J Urol 2015;194:310-315. https://doi.org/10.1016/j.juro.2015.02.013
  6. Anderson CB, Clark PE, Morgan TM, Stratton KL, Herrell SD, Davis R, et al. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology 2011;78:99-104. https://doi.org/10.1016/j.urology.2011.02.039
  7. Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014;25:149-154. https://doi.org/10.1093/annonc/mdt492